MetaCap

Alterity Therapeutics (ATHE) vs Aytu BioPharma (AYTU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Alterity Therapeutics (ATHE) over the past year, gaining 32.3% versus a loss of 56.7%. Over five years, ATHE leads with a -85.4% price change compared with -93.2% for AYTU. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $28.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%AYTU+32.34%
+74%+6%-63%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%AYTU-93.42%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus AYTU key metrics
MetricATHEAYTU
Share price$1.52$2.66
Market cap$29.02M$28.91M
1-day change-8.16%0.00%
YTD return-50.65%+2.31%
1-year return-56.70%+32.34%
5-year return-85.38%-93.21%
Forward P/E—17.16
EPS (TTM)$-0.90$-1.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$57.57M
Revenue growth (YoY)—-13.27%
Net income (latest FY)—$-14.25M
Gross margin—63.95%
Operating margin—-14.44%
Net margin—-24.76%
52-week high$5.89$3.07
52-week low$1.52$1.75
Distance from 52-week high-74.19%-13.36%
Analyst consensusnonestrong_buy
Avg. price target upside+771.71%+263.53%
Average volume89.63K141.18K
Shares outstanding19.09M10.87M
Employees1175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed ATHE by 89.0 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

ATHE vs AYTU FAQ

Which is bigger, Alterity Therapeutics or Aytu BioPharma?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $28.91M for Aytu BioPharma (AYTU).

Which stock has performed better over the past year, ATHE or AYTU?

AYTU returned +32.34% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Aytu BioPharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons